A/Prof Tina Carter on new treatments for young people

A/Prof Tina Carter, paediatric haematologist and Director of the Haemophilia Treatment Centre at Perth Children’s Hospital, spoke with us about current and upcoming treatments, and how this affects young people.

This interview is also available as a podcast. Listen to it on our channel, or search for Bleeding Disorders & Beyond on your preferred podcast app. Alternatively, you can read the transcript below.

Tina was the inaugural Head of Department for the Paediatric and Adolescent Clinical Haematology Service at Perth Children’s Hospital (PCH), where she led the establishment of the service. She is both a clinical and laboratory haematologist, with extensive involvement in clinical trials and translational research across haematology, oncology, and transplantation. She has more than 30 years’ experience in diagnosing and managing haematological disorders including bleeding disorders in neonates, children, and adolescents.

Since 2017, Tina has served as Haemophilia Therapy Director at Princess Margaret Hospital and PCH. She is an active member of the Australian Haemophilia Centre Directors’ Organisation (AHCDO), including five years on its executive committee, and continues to contribute to AHCDO committees, research, and peer-reviewed publications. She has been the Standard 7 (Blood and Blood Products) clinical lead since 2017 and serves as an editor for the Australian Journal of Paediatrics and Child Health. She is also a committed educator and clinical researcher, mentoring medical students, junior doctors, advanced trainees, and multidisciplinary colleagues.

At the opening of PCH in 2018, the clinical haematology unit comprised Tina and a single clinical nurse specialist, Natalie Gamble-Williams. Under her leadership, the service has grown into a multidisciplinary team that includes additional clinical and laboratory haematologists, advanced dual trainees, specialised nursing staff, and allied health professionals. The team delivers comprehensive care across general haematology: including bleeding and thrombosis, bone marrow failure and haemoglobinopathies.

Tina remains dedicated to delivering an integrated and equitable haematology service for children and their families across Western Australia, now and into the future.

Read the interview transcript

Pauline: Hi Tina. Thank you for coming to talk to us about new and emerging haemophilia therapies. First up, could you tell me a little about yourself?

Tina: Yeah, sure. Pauline, I’m one of the clinical and laboratory Haematologists at Perth Children’s [Hospital] in Western Australia, and I’m the HTC director at Perth Children’s and I have been for a number of years now. We manage a number of different haematological conditions at the Children’s Hospital, including bleeding disorders, thrombosis, and bone marrow failure conditions and haemoglobinopathies in neonates, children and adolescents.

Pauline: So adolescents, what age would that be up to?

Tina: It used to be up to 18. It is still 18 if they’re in year 12, but increasingly it’s difficult if they have any procedures or anything beyond 17.

Pauline: So, today we’re chatting to you about new and emerging therapies. And for a young person with haemophilia, what do you think is most exciting about these new therapies? Yeah. 

Evolution of Haemophilia Treatments 

Tina: Well, I’ve been doing this job for a long time. So, as a registrar, I looked after patients who were on blood products and intravenous blood products, and then we switched to recombinant products. Dr Jamie Price was the head of the HTC then, an amazing physician, and he taught us how to manage kids with bleeding disorders, along with his nurse specialist, Sister Lee at the time and the Haemophilia Foundation were very big in WA.

Gavin was really important in terms of giving support to the unit, and so we had a great team, even as a registrar then, I was very lucky.

We managed patients though with intravenous products and the kids, particularly the boys with haemophilia A or a severe von Willebrand disease or severe haemophilia B would, you know, often present with joint bleeds.

So then we went to recombinant products and that was really good. And then I was lucky enough when we moved to the Children’s Hospital to be part of the exec. and part of AHCDO, and really instrumental in getting the long acting factors happening. And that made a massive difference to the kids. You know, they were really not having as many bleeds, which was exciting.

And then, in the last few years, we switched to subcutaneous again with severe haemophilia A mainly subcutaneous protein, proteins if you like, mimics of the factor VIII (8). And that’s just transformed their care. They now have subcutaneous maybe once a week or maybe every fortnight or some monthly and even from infancy. So we don’t have to put the infusaports in.

That’s made a huge difference to the kids coming in for admissions overnight for fevers, and it’s transformed their lives completely.

I mean, they’ll tell you better than me, and the parents will tell you better than me. I mean, some of them don’t even know because we’ve diagnosed them in the last few years what it was like to have intravenous Eloctate at home.

So and you know, we do not see – I know some people do – but we do not see the spontaneous haemarthrosis as often anymore. I haven’t seen one for a long time. We see them associated with mild trauma. So the kids with severe bleeding, Haemophilia A anyway, present with a mild traumatic bleed rather than a severe spontaneous haemarthrosis.

So we’ve seen a lot of change if they’re compliant with their therapy, which they aren’t always compliant, as you know. So that’s amazing. And now looking towards gene therapy and maybe possible cure and some oral therapies.

Pauline: It’s moving fast isn’t it.

Tina: It’s moving really fast. And I think that’s one of the things where a lot of people might look at treatments and think, oh, this is what it used to be. And that’s what it still is. Not realising just how much has changed over the years especially.

Pauline: What do you think within the past decade? It feels like it’s all come about very quickly.

Tina: Yeah, yeah, definitely. In the last ten years or so it’s been huge. Just those long-acting factors giving us, you know, a little bit more control over some events in the kids and like the kids with haemophilia B now, do have access to long-acting factors. 

How New Therapies Work 

Pauline: So some of these therapies. Can you tell me a little bit how they might work differently?

Tina: Obviously they’re all not the same. They work quite differently and different types. Well so the so looking at severe haemophilia A I guess that’s the commonest condition we would treat.

Recombinant long-acting factors

Tina: The recombinant long acting factors have a sort of protein attached to them. And there’s a different number of different ones. They all work in a similar way. And that increases the half-life of the factor 8 in the bloodstream so that when they inject, instead of it having a half-life of 8 hours to 10 hours, and them having this very low trough level, which some of them may remember, might go down to 1 to 2% or even lower. Now what happens is they have the long-acting factor.

And we’ve done the pharmacokinetics on the patients, which we did. All of us did in the when the products first came out. And then we know that we can sort of give them the long-acting factor, and we know their trough, their low level of factor 8 won’t go down below 3% if we give them another dose the next day.

Some of them are a bit faster, some a bit slower, and we were pretty good at sort of doing the analysis on the patients and getting a good feel for how we could use these products.

So they’re the long-acting factors and the long-acting factors in [factor] IX (9) are similar, although in 9 what happens is that peak level doesn’t probably go as high or with some of the recombinant factor 9 products, but we know that the trough stays pretty secure, so you can guarantee that they’re going to have a high trough.

So the trough is the level, the lowest level it goes to before you give another level just to give you that definition. And there’s lots of studies from many decades over the world to show you that, you know, if you get below a level of 3%, that’s when you start getting those spontaneous bleeds into joints and that’s what we want to try and prevent.

So we’ve got much better control with the recombinant factors now.

Sub-cutaneous non-factor therapies

Tina: Now we’ll talk about the other factors where we’ve got the proteins that are developed to be given subcutaneously.

These work like factor 8, they link the factor 9 and factor 10. So they do the job that factor 8 normally does and they’re given subcutaneously. And the amazing thing about them is that once you load the patient up, and that takes probably about 3 to 4 weeks to do that, you get a nice sort of balanced level of about 50% – we think, some patients vary – so we get a sustained level.

And then if they’re compliant with that medication – and that’s in inverted commas “if they’re compliant” – that level will remain about 50%. And we know that those patients on that drug at that level, some of them are a bit like a patient with mild haemophilia, some actually may be even a bit better than that, but they won’t have spontaneous bleeds. And if they have trauma, they won’t have such severe bleeds that they had before, including head injuries, which by the way, I haven’t even mentioned yet, but they’re an important part of our care, trying to prevent severe head injuries, severe bleeds.

And so these drugs keep a really good sort of sustained level if the patient’s compliant. And also knowing that if they have trauma, if they’ve had a head injury or if they’ve been playing sport and they have an injury, they can still have a bleed, but it’s probably not as severe as it would have been before.

However, we also know that some patients do need a little top up if they are participating in very active contact sports, and there are a variety of patients that choose to do this. I had some amazing boys that were really good at soccer who chose to stay on the recombinant factors because they got better control while they were playing soccer.

So there’s a lot of variety of ways that we can sort of nuance their therapy now to match what they’re choosing to do in their lives and at different ages as well, because we know that the boys that are having more physical contact sports might need better cover.

Treatment Choices and Sport 

Pauline: Was there anything else you wanted to share there about, any aspects of new treatments that a young person might need to consider when they’re wanting to choose what new treatment to go on?

Tina: Yeah, we talk about sport a lot in bleeding disorders because, well, as we know, the kids these days are really active, which is fantastic. And again, in my career I’ve seen children hardly doing anything, to children playing active sport and being involved in sport. And of course for some families and some kids, that’s the most important part of their lives. And so as a team, it’s really important for us to support them so that they can do what they want to do.

And these days there are ways of doing that and achieving that if we’ve got them on the right medication.

The other thing that I’ve really noticed over the last few years, as they’ve become more active, is this adolescent group of boys, mainly – girls, not so much – but mainly the boys who might be playing sport in year seven, year eight. So they’ve been playing Auskick or something for, you know, the early years in primary school. And then they get to year seven, year eight, year nine at school and they start to become more physically active. And some of the boys they might be playing against might have gone through puberty a bit earlier, so, you know, they might be 55 kilos, playing against a boy that’s 80 kilos or something. And it’s much more physically active, sort of more physical contact. Say they might be tackling in Australian rules.

It’s a fantastic time actually, because before that they never, ever played those sorts of sports. So now they are. But they have to understand that if they’re going to play that sport, then, if they’ve had a head injury, they might have to consider wearing a helmet. They might actually have to have intravenous treatment, not subcutaneous treatment for those days that they’re playing sport.

And now rugby’s another thing. We don’t play a lot of rugby in Western Australia. So we don’t have a lot of kids playing rugby or, or sort of doing really kickboxing. And those are even other issues that you have to really try and modify their therapy, modify what they’re wearing, their gear just to protect them a little bit.

I think that the families and the kids have to recognise that, we can do this, they can do it, but it has to be in a safe environment. Within those bounds.

Pauline: And I guess at the heart of it, it’s talk to your HTC to get some advice on the right treatment. Let them know what you want to do before it rather than after it. And then they can work with you.

Tina: That’s a good thing actually, Pauline, exactly. Before, not during or afterwards is a really good point.

One of my patients loves downhill racing on his bike – telling us before you’re going to do the sort of downhill racing would be good, not afterwards. And also working with our team because our team, we have physios, great physios on our team and we, and our nursing staff, can just put something together for you so that we can try and support you to do what you want to do. 

Treatment Adherence 

Pauline: You’ve mentioned a few times that they need to be obviously following that treatment regimen. So what are some of the reasons why they might not be following it or adhering to their treatment program as closely as they should?

Tina: Yeah, that’s a good question, Pauline. There’s a number of reasons for that,

I think, over the years I’ve seen that what happens is the young kids, often the little kids, are given their therapy by their parents. And their parents are usually very good at maintaining their therapy. And whether it’s intravenous or subcutaneous, they’ll make sure they get their dosing.

And then what happens is as the children become adolescents and they get, quite rightly, more control over their lives and their how they manage their condition, they may, for a variety of reasons, not be as compliant.

And, you know, that’s part of life, isn’t it? Establishing independence and working out what’s good for you and learning and really, that transition of adolescence to young adulthood is fraught with many different changes.

And we all are very aware that we probably are learning, trying to get better at managing that transition period for kids and young adults, allowing them autonomy and control, but helping them with their compliance. And, you know, sometimes some of them get it very quickly and they realise, okay, I’m responsible for my own health and I have to do my injections. Some of them take a bit longer for a variety of reasons and are, you know, skip, skip some doses. They might, these days, not have ever been on any intravenous factor. And so don’t even appreciate what it is like to have a severe joint bleed. And so until they have one, because they haven’t been compliant with their therapy and missed a few doses, and they don’t understand the way the subcutaneous treatment works, that you can’t miss doses and then just take a dose and it works.

So that’s important that they understand that they can’t miss a dose, and that if they miss 1 or 2 doses, they’re going to be in, you know, if they have an injury or they might even have a spontaneous bleed at those low doses.

So, yes. Complicated.

And then we have a variety of families also who, even for the younger kids, don’t quite understand how the treatments work for the same reasons and may skip a few doses here and there and then have a bleed and then don’t understand why they’ve got a bleed. So yeah, a variety of different reasons why they might not be compliant with therapies.

Tracking Treatments 

Pauline: Do you recommend any tools for recording treatments or keeping track of treatments just to kind of help everyone follow that treatment plan a bit better?

Tina: Yeah. I mean, the ABDR is amazing, isn’t it? The Australian Bleeding Disorder Registry and the ‘My’ apps. You can use MyABDR to monitor if you have a bleed – that’s really useful for us. We can sort of monitor what you’re doing. That’s really good. And then there’s WAPPS as well, which can be useful. I haven’t been using the WAPPS as much, but that’s another app that you can have that can monitor things.

There’s a lot of those sorts of methods and they’re all on your phones on your smartphones these days. Doing photos for us of things is really good as well. Sending us a photo, sending it to the team. ‘Look, this is what happened today. What do you suggest?’ All those things are good. 

Future Therapies and Oral Treatment 

Pauline: So we do have some exciting treatments coming out, such as the oral treatment, inno8, which I believe is in clinical trial. Can you tell me any more about that?

Tina: Yeah. Well, we don’t have that trial open at the moment at the Perth Children’s, but we will definitely have it open as soon as it’s offered to us. This has been sort of on the cards for a while. Some years ago, I think I was at a conference where they first mentioned it, and I was like, no, that’s amazing.

So, a lot of times when you eat, when you take a tablet and you absorb it into your bloodstream, It’s half-life, as you might imagine, doesn’t last very long. It might not even actually get into your bloodstream because it’s broken down by the acid in your stomach. So these new medications have a way of remaining protein bound, so that they’re available for use as a factor. And mostly it’s factor 8 at the moment. But I’m sure in the future it will be other factors as well. And again, keeping that half-life longer.

The half-life is how long it remains in the bloodstream before it’s broken down again. And thinking about that trough level that I talked about earlier. So maintaining a level so the trough level doesn’t go below that sort of magical 3%. So that is really exciting.

That’s an oral medication. And again the danger that will come with that will be being careful about the way it’s absorbed and other things that you take. Maybe if you’re on other medications or your diet. And also then compliance, because compliance will be an important part of how you control, you maintain your level of factor.

And we know that probably a lot of new studies start off in adults, not children. We often trial medications on adults first, then we do children’s studies over 12. And then we do children’s studies under 12. And then we might do infant studies. And that’s the history of medicine generally for lots of different medications. So we have to be patient in paediatrics and adolescents.

Pauline: So I take it this isn’t something that’s going to be available tomorrow. It will take a bit longer than that.

Tina: Yeah. Not for kids for a little while.

Gene Therapy and Closing Thoughts 

Tina: I guess the other thing Pauline, before we finish is I haven’t mentioned gene therapy, which I know you’ll probably do on another podcast, and the other inhibitor therapies that are available, again, they’re amazing.

Gene therapy. It will come in their lifetimes, I have no doubt. I mean, it’s already here, but it will come as a sort of something that is more available to everyone in the future. And these other therapies that we haven’t even mentioned that I’m sure one of the other doctors will mention where you inhibit thrombosis, I haven’t even mentioned them today, but they are other therapies available to patients where you can reduce their bleeding burden. And they are coming around the corner as we speak to all our patients.

So I think it’s a really exciting time for our patients. I think there’s lots of things available to them.

Pauline: Fantastic. Thank you so much for your time today, Tina. I really appreciate you having a chat to me about all of this and letting me know what’s on the cards and what’s coming up.

Tina: Thank you. See you. Bye.

Latest news

Join the HFA community

Sign up for the latest news, events and our free National Haemophilia magazine

Skip to content